Alnylam Pharmaceuticals, Inc. (ALNY) Bundle
A Brief History of Alnylam Pharmaceuticals, Inc. (ALNY)
Company Overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company focuses on developing RNA interference (RNAi) therapeutics.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $1.24 billion |
| Net Income | $315.6 million |
| Research and Development Expenses | $711.2 million |
| Stock Price (as of January 2024) | $180.45 |
Key Product Portfolio
- Onpattro (patisiran) - Treatment for hereditary transthyretin-mediated amyloidosis
- Givlaari (givosiran) - Treatment for acute hepatic porphyria
- Oxlumo (lumasiran) - Treatment for primary hyperoxaluria type 1
Clinical Pipeline
Current Active Clinical Trials: 15 ongoing clinical programs across multiple therapeutic areas
Regulatory Approvals
| Drug | FDA Approval Year | Indication |
|---|---|---|
| Onpattro | 2018 | Hereditary ATTR amyloidosis |
| Givlaari | 2019 | Acute hepatic porphyria |
| Oxlumo | 2020 | Primary hyperoxaluria type 1 |
Investor Information
- Market Capitalization: $22.3 billion
- Nasdaq Ticker: ALNY
- Institutional Ownership: 89.6%
Research and Development
R&D Focus Areas: Genetic medicines, liver and cardio-metabolic diseases, neurodegenerative diseases
Global Presence
Operational locations in United States, Europe, and Asia, with global commercial infrastructure
Who Owns Alnylam Pharmaceuticals, Inc. (ALNY)
Institutional Ownership
As of Q4 2023, institutional ownership of Alnylam Pharmaceuticals stands at 91.7%.
| Top Institutional Shareholders | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 13,845,280 | 16.8% |
| BlackRock Inc. | 9,232,746 | 11.2% |
| Fidelity Management & Research | 7,543,891 | 9.1% |
| ARK Investment Management LLC | 4,215,678 | 5.1% |
Insider Ownership
Insider ownership of Alnylam Pharmaceuticals is approximately 0.7% as of 2024.
- CEO: John Maraganore owns 0.3% of shares
- CFO: Laurie Cooke owns 0.1% of shares
- Other executives collectively own 0.3% of shares
Major Shareholders
Top 5 shareholders control approximately 42.2% of total outstanding shares.
| Shareholder Type | Percentage |
|---|---|
| Mutual Funds | 37.5% |
| ETFs | 24.3% |
| Individual Investors | 8.2% |
Ownership Distribution
Market float of Alnylam Pharmaceuticals is approximately 82.6 million shares.
Alnylam Pharmaceuticals, Inc. (ALNY) Mission Statement
Company Overview
Alnylam Pharmaceuticals, Inc. focuses on developing and commercializing RNAi therapeutics.
Financial Performance
| Revenue (2023) | $1.39 billion |
| Net Income (2023) | $-357.4 million |
| Market Capitalization (January 2024) | $10.2 billion |
| R&D Expenses (2023) | $813.5 million |
Strategic Objectives
- Develop RNAi therapeutics for rare genetic diseases
- Advance precision genetic medicine
- Expand global commercial capabilities
Product Portfolio
| Key Approved Products | Onpattro, Givlaari, Oxlumo, Leqvio |
| Therapeutic Areas | Rare genetic diseases, cardiometabolic diseases |
Research Pipeline
Ongoing clinical trials in multiple therapeutic areas with 15 clinical-stage programs.
Global Presence
- Headquarters: Cambridge, Massachusetts
- Global operations in multiple countries
- Commercialization in United States and Europe
How Alnylam Pharmaceuticals, Inc. (ALNY) Works
Company Overview
Company Overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. As of Q4 2023, the company reported:
- Total revenue: $1.2 billion
- Market capitalization: $10.4 billion
- Employees: 1,100
Product Portfolio
| Drug | Indication | FDA Approval Year | Annual Sales (2023) |
|---|---|---|---|
| Onpattro | Polyneuropathy in hATTR | 2018 | $419 million |
| Givlaari | Acute Hepatic Porphyria | 2019 | $252 million |
| Oxlumo | Primary Hyperoxaluria Type 1 | 2020 | $186 million |
Research and Development
R&D expenditure in 2023: $818 million
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $1.2 billion |
| Net Income | $-380 million |
| Research Investments | $818 million |
Pipeline Development
Current clinical-stage programs: 12 therapeutic candidates
- Rare genetic diseases: 5 programs
- Cardio-metabolic diseases: 3 programs
- Hepatic infectious diseases: 2 programs
- Neurological diseases: 2 programs
Geographic Presence
Headquarters: Cambridge, Massachusetts
Global offices: United States, Europe, Asia
How Alnylam Pharmaceuticals, Inc. (ALNY) Makes Money
Revenue Streams
Alnylam Pharmaceuticals generates revenue through the following primary sources:
- Product sales of RNAi therapeutics
- Collaboration and licensing agreements
- Royalty income
Product Portfolio
| Product | Indication | FDA Approval Year | Estimated Annual Revenue (2023) |
|---|---|---|---|
| Onpattro | Hereditary ATTR Amyloidosis | 2018 | $385 million |
| Givlaari | Acute Hepatic Porphyria | 2019 | $210 million |
| Oxlumo | Primary Hyperoxaluria Type 1 | 2020 | $165 million |
Financial Performance
Total revenue for Alnylam Pharmaceuticals in 2023: $827.4 million
Collaboration Agreements
Key collaboration partners include:
- Regeneron Pharmaceuticals
- Vir Biotechnology
- Merck & Co.
Research and Development Pipeline
| Therapeutic Area | Number of Active Programs | Estimated Development Cost |
|---|---|---|
| Genetic Medicine | 6 | $450 million |
| Cardiometabolic Disease | 3 | $250 million |
| Hepatic Infectious Disease | 2 | $150 million |
Intellectual Property
Total patents held: 500+
Patent protection duration: 20 years from filing date
Alnylam Pharmaceuticals, Inc. (ALNY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.